Publicaciones en colaboración con investigadores/as de Assistance Publique -Hopitaux De Paris (32)

2023

  1. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

    Cytometry Part B - Clinical Cytometry, Vol. 104, Núm. 1, pp. 77-86

  2. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  3. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  4. European Society of Thoracic Surgeons expert consensus recommendations on technical standards of segmentectomy for primary lung cancer

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 63, Núm. 6

  5. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet

    Cytometry Part B - Clinical Cytometry, Vol. 104, Núm. 1, pp. 15-26

  6. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group

    Cytometry Part B - Clinical Cytometry, Vol. 104, Núm. 1, pp. 27-50

  7. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 15, pp. 2827-2842

2022

  1. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

    Blood, Vol. 140, Núm. 26, pp. 2773-2787

  2. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022

    Journal of Allergy and Clinical Immunology, Vol. 149, Núm. 6, pp. 1855-1865

2021

  1. Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1867, Núm. 4

  2. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet

    Cytometry Part B - Clinical Cytometry

  3. Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection

    BJS Open

  4. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

    Leukemia, Vol. 35, Núm. 12, pp. 3585-3588

2020

  1. Cold-atmospheric plasma induces tumor cell death in preclinical in vivo and in vitro models of human cholangiocarcinoma

    Cancers, Vol. 12, Núm. 5

  2. Distinct mutational pattern of myelodysplastic syndromes with and without 5q– treated with lenalidomide

    British Journal of Haematology

  3. Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

    British Journal of Haematology, Vol. 189, Núm. 1, pp. 84-96

  4. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

    Haematologica, Vol. 105, Núm. 2, pp. 297-316

  5. Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents

    Leukemia Research

2019

  1. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: Long-term results of the PRIMA study

    Journal of Clinical Oncology, Vol. 37, Núm. 31, pp. 2815-2824

2018

  1. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

    British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359